Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the drug INCA033989 compared with the best available therapy in participants who have essential thrombocythemia ET with a CALR mutation and who have previously been treated with cytoreductive therapy. This phase 3, randomized, open-label study aims to assess the treatment effects in this specific group of patients with high-risk ET. Participants will receive either INCA033989 administered intravenously according to the study protocol or the best available therapy chosen by the investigator. The study treatments are given in parallel groups and will be monitored to compare responses and safety. The main study period includes treatment and observation up to at least 48 weeks, with follow-up for adverse events for 60 days after the last dose. During the study, participants will attend regular visits for assessments including clinical and hematologic responses, mutation frequency measurements, symptom assessments, and fatigue evaluations. Researchers will monitor treatment-emergent adverse events and measure durable responses at weeks 24 and 48. The total study duration extends until November 2030, with ongoing monitoring of patient health and responses throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are comparing the effectiveness and safety of sonrotoclax combined with either obinutuzumab or rituximab against venetoclax combined with rituximab in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase 3 study aims to assess progression-free survival and other important outcomes among these treatment combinations to find better options for patients. Participants will be randomly assigned to one of four treatment groups sonrotoclax plus obinutuzumab, sonrotoclax plus rituximab, sonrotoclax plus obinutuzumab guided by minimal residual disease evaluation, or venetoclax plus rituximab. Sonrotoclax and venetoclax are given orally, while obinutuzumab and rituximab are given intravenously. The study includes detailed treatment schedules and monitoring of minimal residual disease in one group. During the study, participants will have regular evaluations including assessments by blinded independent review committees of progression-free survival, response rates, and overall survival. Quality of life and symptom burden will also be measured using specific questionnaires. Safety will be monitored from the first dose through follow-up periods lasting up to several years. The total study duration extends to approximately six years, with ongoing assessments to understand treatment effects and safety.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.
Actively Recruiting
Researchers are evaluating the safety of new dosing schedules for sonrotoclax in adults with blood cancers, specifically chronic lymphocytic leukemia CLL and mantle cell lymphoma MCL. The study aims to find the best way to gradually increase the sonrotoclax dose to reduce risks such as tumor lysis syndrome TLS and related toxicities. This trial is a phase 12 open-label study supported by BeOne Medicines. Participants will start treatment with zanubrutinib alone, an approved drug that targets malignant B cells, followed by a combination of zanubrutinib and sonrotoclax. Sonrotoclax dosing will be increased gradually according to different schedules to reach the target daily dose. Treatment cycles last 28 days each, with 15 cycles for treatment-nave CLL patients and up to 27 cycles for relapsedrefractory MCL patients, who may continue zanubrutinib alone until disease progression or other criteria are met. During the study, participants will be monitored closely for safety, especially for signs of TLS and adverse events during approximately four months of dose ramp-up. Researchers will collect data on dose modifications and overall tolerability. The total participation time is about 17 months for treatment-nave CLL patients and up to 32 months for relapsedrefractory MCL patients, with ongoing assessments throughout the treatment period.
Actively Recruiting
Researchers are conducting a global, multicenter, randomized, double-blind, placebo-controlled pivotal phase III study to evaluate overall survival in patients with newly diagnosed higher-risk myelodysplastic syndrome HR-MDS. The study compares the combination of lisaftoclax APG-2575 and azacitidine AZA against placebo combined with azacitidine. This trial aims to better understand treatment outcomes in this patient group. Participants receive either lisaftoclax orally once daily combined with azacitidine administered by hypodermic or intravenous injection once daily, or placebo orally once daily combined with azacitidine. The study includes two groups running in parallel. Treatment and follow-up continue for up to five years to assess long-term outcomes. During the study, participants will undergo regular evaluations including assessments of overall survival and safety, specifically monitoring adverse events over the five-year period. Participants must be able to complete study procedures and follow-up examinations. The study involves informed consent and ongoing monitoring to ensure participant safety and adherence.